Patent intelligence · US
US 11370769
TRPC5 inhibitors and methods of using same
TRPC5 inhibitors and methods of using same
Patent details — US 11370769
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 28, 2022
- Expiration
- Jun 23, 2042
- Claims
- 14
- CPC classes
- A61P, A61P13/12
Quick answer
US 11370769 (TRPC5 inhibitors and methods of using same) is held by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA. Status: granted. Granted Jun 28, 2022. Expires Jun 23, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P13/12
More from BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11370769?
US 11370769 (TRPC5 inhibitors and methods of using same) is held by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA. Status: granted. Granted Jun 28, 2022. Expires Jun 23, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11370769?
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11370769 expire?
Our index shows an expiration date of Jun 23, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.